22 February 2021 - Innovent Biologics today jointly announce that the Center for Drug Evaluation of China's National Medical Products Administration has granted breakthrough therapy designation for the investigational chimeric antigen receptor-T cell therapy co-developed by Innovent and IASO for treatment of relapsed/refractory multiple myeloma.
The breakthrough therapy designation for IBI326 is based on the results observed in ongoing Phase 1/2 study for the treatment of adults with relapsed or refractory multiple myeloma being conducted in China.